Acasti Pharma Statistics
Share Statistics
Acasti Pharma has 10.14M shares outstanding. The number of shares has increased by 7.88% in one year.
| Shares Outstanding | 10.14M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 7.88% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 4.65M |
| Failed to Deliver (FTD) Shares | 5.93K |
| FTD / Avg. Volume | 19.71% |
Short Selling Information
The latest short interest is 154.19K, so 1.52% of the outstanding shares have been sold short.
| Short Interest | 154.19K |
| Short % of Shares Out | 1.52% |
| Short % of Float | 2.47% |
| Short Ratio (days to cover) | 3.84 |
Valuation Ratios
The PE ratio is -2.56 and the forward PE ratio is -2.67.
| PE Ratio | -2.56 |
| Forward PE | -2.67 |
| PS Ratio | 0 |
| Forward PS | null |
| PB Ratio | 0.53 |
| P/FCF Ratio | -2.66 |
| PEG Ratio | n/a |
Enterprise Valuation
Acasti Pharma Inc. has an Enterprise Value (EV) of -.
| EV / Earnings | null |
| EV / Sales | null |
| EV / EBITDA | null |
| EV / EBIT | null |
| EV / FCF | null |
Financial Position
The company has a current ratio of 14.26, with a Debt / Equity ratio of 0.
| Current Ratio | 14.26 |
| Quick Ratio | 14.26 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0 |
| Cash Flow / Debt | 0 |
| Interest Coverage | -12.42 |
Financial Efficiency
Return on equity (ROE) is -0.21% and return on capital (ROIC) is -16.1%.
| Return on Equity (ROE) | -0.21% |
| Return on Assets (ROA) | -0.18% |
| Return on Capital (ROIC) | -16.1% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -401.66K |
| Employee Count | 32 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | -1.78M |
| Effective Tax Rate | 0.12 |
Stock Price Statistics
The stock price has increased by 42.79% in the last 52 weeks. The beta is 1.52, so Acasti Pharma 's price volatility has been higher than the market average.
| Beta | 1.52 |
| 52-Week Price Change | 42.79% |
| 50-Day Moving Average | 2.83 |
| 200-Day Moving Average | 2.92 |
| Relative Strength Index (RSI) | 58.05 |
| Average Volume (20 Days) | 30.06K |
Income Statement
In the last 12 months, Acasti Pharma had revenue of $0 and earned -$12.85M in profits. Earnings per share was $-1.35.
| Revenue | 0 |
| Gross Profit | -11.00K |
| Operating Income | -11.31M |
| Net Income | -12.85M |
| EBITDA | -11.30M |
| EBIT | - |
| Earnings Per Share (EPS) | -1.35 |
Balance Sheet
The company has $23.00M in cash and $0 in debt, giving a net cash position of $23.00M.
| Cash & Cash Equivalents | 23.00M |
| Total Debt | 0 |
| Net Cash | 23.00M |
| Retained Earnings | -211.12M |
| Total Assets | 69.72M |
| Working Capital | 17.83M |
Cash Flow
In the last 12 months, operating cash flow was -$12.33M and capital expenditures -$22.00K, giving a free cash flow of -$12.36M.
| Operating Cash Flow | -12.33M |
| Capital Expenditures | -22.00K |
| Free Cash Flow | -12.36M |
| FCF Per Share | -1.3 |
Margins
Gross margin is 0%, with operating and profit margins of 0% and 0%.
| Gross Margin | 0% |
| Operating Margin | 0% |
| Pretax Margin | 0% |
| Profit Margin | 0% |
| EBITDA Margin | n/a% |
| EBIT Margin | n/a% |
| FCF Margin | n/a% |
Dividends & Yields
ACST does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -40.06% |
| FCF Yield | -36.16% |
Analyst Forecast
The average price target for ACST is $10, which is 196.7% higher than the current price. The consensus rating is "Buy".
| Price Target | $10 |
| Price Target Difference | 196.7% |
| Analyst Consensus | Buy |
| Analyst Count | 2 |
Stock Splits
The last stock split was on Jul 10, 2023. It was a backward split with a ratio of 1:6.
| Last Split Date | Jul 10, 2023 |
| Split Type | backward |
| Split Ratio | 1:6 |
Scores
| Altman Z-Score | -2.74 |
| Piotroski F-Score | 2 |